isocyanato-methanesulfonyl-methane | 1161826-12-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: isocyanato-methanesulfonyl-methane
• 英文别名: isocyanato(methylsulfonyl)methane；Isocyanato(methanesulfonyl)methane
• CAS: 1161826-12-5
• 化学式: C₃H₅NO₃S
• mdl: MFCD19632225
• 分子量: 135.144
• InChiKey: KLBXRKHTNWQTNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  72
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  isocyanato-methanesulfonyl-methane 、 4-重氮基-4H-咪唑-5-甲酰胺 以 二甲基亚砜 为溶剂， 反应 24.0h， 以68%的产率得到3-methanesulfonylmethyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide
  参考文献：
  名称：

  抗肿瘤咪唑并[5,1- d ] -1,2,3,5-四嗪类化合物：在3位修饰的化合物克服了人胶质母细胞瘤细胞系的耐药性† ‡

  摘要：

  探索了与替莫唑胺结构相关的3-取代的咪唑并[5,1- d ] -1,2,3,5-四嗪的合成途径。当以可接受的纯度获得异氰酸酯时，4-重氮咪唑-5-羧酰胺与异氰酸酯的相互作用提供了高产物收率。可选地，正-替唑啉酰亚胺阴离子的烷基化提供了高产率的新的咪唑并四嗪。针对含有匹配的MGMT±胶质瘤细胞系的一组化合物评估的几种化合物，无论MGMT的状态如何，均表现出相同的抑制活性。N3-炔丙基-咪唑并四嗪（10m）被优先作为替莫唑胺的替代品，后者能够绕过耐药机制。在Taq聚合酶测定法10m像替莫唑胺及其开环对应物MTIC一样，在三个和五个鸟嘌呤残基簇上的烷基化DNA；在哌啶裂解试验中检测到鸟嘌呤N-7位的共价修饰。化合物10m没有交联DNA，但是通过γ-H2AX检测证明诱导了双链断裂。炔丙基取代的咪唑三嗪（13g）显示出与10m相当的活性，表明新的咪唑四嗪的双环核开环可能是活性所必需的。

  DOI：

  10.1039/c6md00384b
• 作为产物：
  描述：

  甲磺酰乙酸甲酯 在 肼 、 盐酸 、 sodium nitrite 作用下， 以 乙醇 、 氯仿 、 水 为溶剂， 反应 1.58h， 以51%的产率得到isocyanato-methanesulfonyl-methane
  参考文献：
  名称：

  [EN] 3-SUBSTITUTED-4-0X0-3, 4-DIHYDRO-IMIDAZO- [5, 1-D] [1,2,3,5] -TETRAZINE-8-CARBOXYLIC ACID AMIDES AS ANTICANCER AGENTS
  [FR] AMIDES D'ACIDES 4-OXO-3,4-DIHYDROIMIDAZO[5,1-D][1,2,3,5-TÉTRAZINE-8-CARBOXYLIQUES SUBSTITUÉS EN POSITION 3 ET LEUR UTILISATION

  摘要：

  公开号：

  WO2009077741A3

文献信息

• [EN] 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS 3H-IMIDAZO[5,1-D][1,2,3,5-TÉTRAZIN-4-ONE 3-SUBSTITUÉS-8-SUBSTITUÉS ET LEUR UTILISATION
  申请人：PHARMINOX LTD

  公开号：WO2010149968A1

  公开（公告）日：2010-12-29

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds of the following formula, wherein -A and -B are as defined herein (collectively referred to herein as 38TM compounds): (1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明一般涉及治疗化合物领域，更具体地涉及以下公式的3-取代-8-取代-3H-咪唑[5,1-d][1,2,3,5]四唑-4-酮化合物，其中-A和-B如本文所定义（统称为38TM化合物）：（1）。本发明还涉及包含这种化合物的药物组合物，以及利用这种化合物和组合物在体外和体内抑制细胞增殖，治疗增生性疾病如癌症等的用途，以及制备这种化合物的方法。
• Synthesis of a 6-Aza-Isoindolinone-Based Inhibitor of Phosphoinositide 3-Kinase γ via Ruthenium-Catalyzed [2 + 2 + 2] Cyclotrimerization
  作者：Philip N. Collier、Advaita Panchagnula、Hardwin O’Dowd、Arnaud Le Tiran、Alex M. Aronov

  DOI：10.1021/acsmedchemlett.8b00530

  日期：2019.1.10

  We have developed a synthesis of a novel PI3Kγ inhibitor containing a 1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one scaffold. The key step in the synthesis involved a ruthenium-catalyzed [2 + 2 + 2] cyclotrimerization reaction between a diyne and an alkoxycarbonyl isocyanate, a previously unreported coupling partner in such a reaction.

  磷酸肌醇3-激酶（PI3Kγ）是一种药物靶标，与多种疾病的治疗有关。我们已经开发了一种新型的PI3Kγ抑制剂的合成，该抑制剂包含1,2-二氢-3H-吡咯并[3,4-c]吡啶-3-酮骨架。合成中的关键步骤涉及二炔与烷氧基羰基异氰酸酯之间的钌催化的[2 + 2 + 2]环三聚反应，该反应中以前没有报道过偶合伙伴。
• 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use
  申请人：Stevens Malcolm Francis Graham

  公开号：US20100286088A1

  公开（公告）日：2010-11-11

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明涉及治疗化合物领域，更具体地涉及某些3-取代-4-氧代-3,4-二氢咪唑[5,1-d][1,2,3,5]四嗪-8-羧酸酰胺（统称为3TM化合物）。本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制细胞增殖，在治疗增生性疾病如癌症等方面的应用，以及制备这种化合物的方法。
• 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use
  申请人：Hummersone Marc Geoffery

  公开号：US20120083513A1

  公开（公告）日：2012-04-05

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds of the following formula, wherein -A and —B are as defined herein (collectively referred to herein as 38TM compounds): The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明涉及治疗化合物领域，更具体地涉及以下式子的3-取代-8-取代-3H-咪唑[5,1-d][1,2,3,5]四唑-4-酮化合物，其中-A和—B在此定义（统称为38TM化合物）：本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制细胞增殖，治疗增殖性疾病如癌症等，以及制备这种化合物的方法。
• 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use
  申请人：Stevens Malcolm Francis Graham

  公开号：US08450479B2

  公开（公告）日：2013-05-28

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明涉及治疗化合物领域，更具体地涉及某些3-取代-4-氧代-3,4-二氢咪唑[5,1-d][1,2,3,5]四嗪-8-羧酸酰胺（统称为3TM化合物）。本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制细胞增殖，治疗增殖性疾病如癌症等，以及制备这种化合物的方法。